The three types of conjugates (i.e., QD800-RGD, QD820-anti-CEACAM1, and QD840-anti-EGFR) were simultaneously detected in vivo, especially showed great potential to be used for tumor targeting agents with specific delineation of tumor region (Fig. 3D). This evidence concerns the gene EGFR and neoplasm.